VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC

被引：10
|
作者：
Hochmair, M. J. [1 ]
Vermaelen, K. [2 ]
Mountzios, G. [3 ,4 ]
Carcereny, E. [5 ]
Dooms, C. [6 ]
Lee, S. -h. [7 ]
Morocz, E. M. [8 ]
Kato, T. [9 ]
Ciuleanu, T-e. [10 ]
Dy, G. [11 ]
Parente, M. B. M. C. S. [12 ]
O'Byrne, K. J. [13 ]
Chu, Q. s -c. [14 ]
De Castro Jr, G. [14 ]
Girard, N. [15 ]
Snyder, W. [16 ]
Tran, Q. [16 ]
Kormany, W. [16 ]
Houk, B. [16 ]
Curioni-Fontecedro, A. [17 ]
机构：
[1] Karl Landsteiner Inst Lung Res & Pulm Oncol, Dept Resp & Crit Care Med, Klin Florisdorf, Vienna, Austria
[2] UZ Gent Univ Ziekenhuis Gent, Dept Pulm Med, Ghent, Belgium
[3] Henry Dunant Hosp Ctr, Dept Med Oncol 4, Athens 11526, Greece
[4] Henry Dunant Hosp Ctr, Clin Trials Unit, Athens, Greece
[5] Catalan Inst Oncol Badalona, Badalona Appl Res Grp Oncol, Med Oncol, Badalona, Spain
[6] Univ Hosp KU Leuven, Dept Resp Dis, Leuven, Belgium
[7] Sungkyunkwan Univ, Samsung Med Ctr SMC, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea
[8] Pest Cty Hosp Pulmonol, Pulmonolgy, Torokbalint, Hungary
[9] Kanagawa Canc Ctr, Thorac Oncol Dept, Yokohama, Japan
[10] IOCN Oncol Inst Prof Dr Ion Chiricuta, Med Oncol Dept, Cluj Napoca, Romania
[11] Roswell Park Comprehens Canc Ctr, Med Dept, Buffalo, NY USA
[12] CHVNG E Ctr Hosp Vila Nova Gaia Espinho, Unidade 1, Pulmonol, EPE SNS, Porto, Portugal
[13] Princess Alexandra Hosp, Canc Serv, Metro South Hlth, Woolloongabba, Qld, Australia
[14] Univ Alberta, Cross Canc Inst, Med Oncol, Edmonton, AB, Canada
[15] Thorax Inst, Inst Curie, Paris, France
[16] Amgen Inc, Oncol, Thousand Oaks, CA USA
[17] Univ Hosp Zurich, Dept Med Oncol & Hematol, Zurich, Switzerland
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷 / 01期
关键词：
D O I：
10.1016/j.annonc.2023.10.790
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：142 / 144
页数：3
相关论文
共 50 条
  • [21] Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC
    Burns, Timothy F.
    Dragnev, Konstantin
    Fujiwara, Yutaka
    Murciano-Goroff, Yonina R.
    Lee, Dae Ho
    Hollebecque, Antoine
    Koyama, Takafumi
    Cassier, Philippe
    Italiano, Antoine
    Heist, Rebecca S.
    Han, Ji-Youn
    Deming, Dustin
    Spira, Alexander
    Sabari, Joshua
    Chisamore, Michael J.
    Fink, Aaron
    Chen, Aaron
    Willard, Melinda D.
    Oxnard, Geoffrey R.
    Ammakkanavar, Natraj Reddy
    Pruthi, Aarohan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 137 - 138
  • [22] Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC
    Burns, Timothy F.
    Dragnev, Konstantin H.
    Fujiwara, Yutaka
    Murciano-Goroff, Yonina R.
    Lee, Dae Ho
    Hollebecque, Antoine
    Koyama, Takafumi
    Cassier, Philippe Alexandre
    Italiano, Antoine
    Heist, Rebecca Suk
    Han, Ji-Youn
    Deming, Dustin A.
    Spira, Alexander I.
    Sabari, Joshua K.
    Chisamore, Michael Jon
    Fink, Aaron Alan
    Chen, Aaron
    Willard, Melinda D.
    Oxnard, Geoffrey R.
    Ammakkanavar, Natraj Reddy
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203).
    Govindan, Ramaswamy
    Awad, Mark M.
    Gadgeel, Shirish M.
    Pachter, Jonathan A.
    Patrick, Gloria
    Denis, Louis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [24] Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C
    Griesinger, F.
    Eberhardt, W.
    Hoffknecht, P.
    Metzenmacher, M.
    Wehler, T.
    Kokowski, K.
    Alt, J.
    Schuette, W.
    Jaenicke, M.
    Fleitz, A.
    Zacharias, S.
    Hipper, A.
    Buller, M.
    Weichert, W.
    Groschek, M.
    von der Heyde, E.
    Rauh, J.
    Dechow, T.
    Sebastian, M.
    Thomas, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 135 - 135
  • [25] Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C
    Griesinger, F.
    Eberhardt, W. E. E.
    Hoffknecht, P.
    Metzenmacher, M.
    Wehler, T.
    Kokowski, K.
    Alt, J.
    Schuette, W.
    Jaenicke, M.
    Fleitz, A.
    Zacharias, S.
    Hipper, A.
    Buller, M.
    Weichert, W.
    Groschek, M.
    von der Heyde, E.
    Rauh, J.
    Dechow, T.
    Sebastian, M.
    Thomas, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S872 - S872
  • [26] Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.
    Fujiwara, Yutaka
    Burns, Timothy F.
    Dragnev, Konstantin H.
    Murciano-Goroff, Yonina R.
    Lee, Dae Ho
    Hollebecque, Antoine
    Koyama, Takafumi
    Cassier, Philippe Alexandre
    Italiano, Antoine
    Heist, Rebecca Suk
    Han, Ji-Youn
    Deming, Dustin A.
    Spira, Alexander I.
    Sabari, Joshua K.
    Chisamore, Michael Jon
    Fink, Aaron Alan
    Chen, Aaron
    Willard, Melinda D.
    Oxnard, Geoffrey R.
    Ammakkanavar, Natraj Reddy
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : 195 - 195
  • [27] Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC)
    Skoulidis, Ferdinandos
    De langen, Adrianus
    Paz-Ares, Luis G.
    Mountzios, Giannis Socrates
    Curioni-Fontecedro, Alessandra
    Couraud, Sebastien
    Janssens, Annelies
    Rocco, Danilo
    Ohashi, Kadoaki
    Vincent, Mark David
    Kang, Jin-Hyoung
    Schvartsman, Gustavo
    Lindsay, Colin R.
    O'Byrne, Kenneth John
    Dziadziuszko, Rafal
    Andersen, Jon A. Lykkegaard
    Hindoyan, Antreas
    Wilmanski, Tomasz
    Wang, Yang
    Schuler, Martin H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC
    Li, B. T.
    Falchook, G. S.
    Durm, G. A.
    Burns, T. F.
    Skoulidis, F.
    Ramalingam, S. S.
    Spira, A.
    Bestvina, C. M.
    Goldberg, S. B.
    Veluswamy, R.
    Iams, W. T.
    Chiappori, A. A.
    Lemech, C. R.
    Meloni, A. R.
    Ebiana, V.
    Dai, T.
    Gauto, D. M.
    Varrieur, T. L.
    Snyder, W. J.
    Govindan, R.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S10 - S11
  • [29] Sotorasib vs Adagrasib: Matching-adjusted Indirect Comparison in Prior Treated KRAS G12C Advanced Non-Small Cell Lung Cancer
    Chopra, D.
    Waterhouse, D. M.
    Sylvester, B.
    Jamotte, A.
    Stollenwerk, B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S647 - S648
  • [30] Sotorasib in KRAS p.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program
    Reale, M. L.
    Passiglia, F.
    Brambilla, M.
    Pasello, G.
    Minuti, G.
    Bulotta, A.
    Pizzutilo, P.
    Sini, C.
    Costa, J.
    Roca, E.
    Bria, E.
    Pilotto, S.
    Genova, C.
    Metro, G.
    Citarella, F.
    Bordi, P.
    Russo, A.
    Chiari, R.
    Andrikou, K.
    Novello, S.
    ANNALS OF ONCOLOGY, 2023, 34
12345